Status:

UNKNOWN

MORE in the Management of Lumbosacral Radiculopathy Symptoms: A Randomized Controlled Trial

Lead Sponsor:

National University of Natural Medicine

Conditions:

Lumbar Radiculopathy

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

INTRODUCTION: Chronic low back pain (CLBP) is a ubiquitous musculoskeletal (MSK) complaint that often presents as a chronic and difficult to treat condition. Lumbosacral radiculopathy/radiculitis (LR)...

Eligibility Criteria

Inclusion

  • 1: Presence of previous diagnosis of LR
  • 1a: Presence of lumbosacral radiculopathy/radiculitis symptoms that extend below the knee secondary to low back pain for greater than 6 weeks with a painDETECT score greater than 18 OR.
  • 1b: Diagnosis of lumbosacral radiculopathy/radiculitis secondary to low back pain that extends below the knee, with symptoms present for greater than 6 weeks.
  • 1b.1: ICD-10 codes used for diagnostic inclusion: M54.16, M54.17, M51.16, M51.17, M47.26, M47.27, M54.40, M54.41, M54.42, M99.53, M99.54, S34.21, S34.22, G54.4, and G55
  • 2: At least 18 years of age and not older than 64 at the time of study enrollment.
  • 3: Ability to read and understand English.
  • 4: Willingness to be randomized to either an experimental or a control group.
  • 5: Willingness to refrain from unnecessary or self-directed pain management/treatment plan changes during study enrollment and to report necessary changes made.
  • 6: Daily access to the internet via cell phone, tablet, or computer.

Exclusion

  • Epidural steroid injection in the prior 3 months.
  • Inability to complete 20 unassisted gait cycles.
  • Have received a surgical intervention for low back pain or lumbosacral radiculopathy/radiculitis within the previous 6 months.
  • Current active mindfulness meditation practice: 1 time/week or more and/or formal training in mindfulness/meditation practice.
  • Concurrent diagnosis of cancer.
  • Allergy or intolerance to adhesive.
  • Current unmanaged or uncontrolled mental illness known to cause psychosis: schizophrenia and schizotypal disorders, bipolar I disorder with psychosis, major depressive disorder with psychosis.

Key Trial Info

Start Date :

February 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2022

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04818606

Start Date

February 1 2021

End Date

March 1 2022

Last Update

March 26 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National University of Natural Medicine Helfgott Research Institute

Portland, Oregon, United States, 97201